FibroGen Inc (FGEN)
0.3699
+0.04
(+11.35%)
USD |
NASDAQ |
Nov 14, 16:00
0.3502
-0.02
(-5.33%)
After-Hours: 06:44
FibroGen Free Cash Flow (Quarterly): -39.88M for June 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -39.88M |
March 31, 2024 | -59.32M |
December 31, 2023 | -18.57M |
September 30, 2023 | -85.22M |
June 30, 2023 | -111.56M |
March 31, 2023 | -102.18M |
December 31, 2022 | -52.85M |
September 30, 2022 | -52.74M |
June 30, 2022 | -33.97M |
March 31, 2022 | -45.11M |
December 31, 2021 | -56.36M |
September 30, 2021 | 17.68M |
June 30, 2021 | -28.24M |
March 31, 2021 | -45.50M |
December 31, 2020 | -9.618M |
September 30, 2020 | -1.768M |
June 30, 2020 | 148.94M |
March 31, 2020 | -59.94M |
December 31, 2019 | -46.80M |
September 30, 2019 | -29.29M |
June 30, 2019 | -30.38M |
Date | Value |
---|---|
March 31, 2019 | 22.00M |
December 31, 2018 | -20.63M |
September 30, 2018 | 7.101M |
June 30, 2018 | -36.83M |
March 31, 2018 | -33.80M |
December 31, 2017 | -4.694M |
September 30, 2017 | -21.81M |
June 30, 2017 | -20.73M |
March 31, 2017 | -27.77M |
December 31, 2016 | -18.69M |
September 30, 2016 | -1.854M |
June 30, 2016 | 44.56M |
March 31, 2016 | -18.16M |
December 31, 2015 | -39.61M |
September 30, 2015 | -38.80M |
June 30, 2015 | 100.51M |
March 31, 2015 | -42.64M |
December 31, 2014 | -26.34M |
September 30, 2014 | -32.65M |
June 30, 2014 | 91.14M |
March 31, 2014 | -17.85M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-111.56M
Minimum
Jun 2023
148.94M
Maximum
Jun 2020
-35.95M
Average
-45.50M
Median
Mar 2021
Free Cash Flow (Quarterly) Benchmarks
Biomarin Pharmaceutical Inc | 200.30M |
Arbutus Biopharma Corp | -20.74M |
GlycoMimetics Inc | -8.896M |
Cidara Therapeutics Inc | -36.80M |
Cue Biopharma Inc | -10.00M |